Replies to post #196778 on Biotech Values

[DewDiligence]

ADXS +6% on this somewhat fluffy PR:

http://finance.yahoo.com/news/advaxis-presents-data-featuring-lm-140500236.html

Oddly, today's pop was bigger than the one ADXS got last Tuesday, when the FDA acknowledged that the patient death causing the clinical hold was not drug-related (#msg-118199780).

[DewDiligence]

ADXS executive officers continue small monthly purchases despite FDA clinical hold:

http://www.sec.gov/Archives/edgar/data/1100397/000149315215005982/xslF345X03/form4.xml (CEO)
http://www.sec.gov/Archives/edgar/data/1100397/000149315215005984/xslF345X03/form4.xml (COO)
http://www.sec.gov/Archives/edgar/data/1100397/000149315215005983/xslF345X03/form4.xml (CMO)
http://www.sec.gov/Archives/edgar/data/1100397/000149315215005980/xslF345X03/form4.xml (CSO)
http://www.sec.gov/Archives/edgar/data/1100397/000149315215005981/xslF345X03/form4.xml (CFO)

Better than insider selling, LOL.

[DewDiligence]

ADXS +37%/AH on lifting of FDA clinical hold:

http://finance.yahoo.com/news/fda-lifts-advaxis-clinical-hold-140500557.html

…the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac (formerly ADXS-HPV), ADXS-PSA and ADXS-HER2. Advaxis will therefore resume all clinical trials with axalimogene filolisbac, ADXS-PSA and ADXS-HER2.

The FDA acknowledged in November that the patient death that lead to the clinical hold was not drug-related (#msg-118199780), so formal lifting of the clinical hold was a matter of when the FDA would get around to it.